PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry Genetics

Genetic Testing for Prostate Cancer: Advances and Considerations | Webinar | Ambry GeneticsПодробнее

Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy | Webinar | Ambry GeneticsПодробнее

PARP Inhibitors in Ovarian Cancer Treatment | Webinar | Ambry GeneticsПодробнее

Webinar: PARP Inhibitors and Ovarian CancerПодробнее

Dr. Penson on the Eligibility Criteria for PARP Inhibitors in Advanced Ovarian CancerПодробнее

Combinations May Combat PARP ResistanceПодробнее

Expert Weighs In On The Future of PARP InhibitorsПодробнее

Sequencing PARP Inhibitors in Advanced Ovarian CancerПодробнее

Understanding the Side Effects of PARP InhibitorsПодробнее

PARP Inhibitors in Recurrent Ovarian CancerПодробнее

PARP Inhibition’s Role in Recurrent Ovarian CancerПодробнее

Role of Immunotherapy and PARP InhibitorsПодробнее

PARP Inhibitors in Other Subtypes of Breast CancerПодробнее

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian CancerПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее

Looking to the Future of PARP Inhibitors in CRPCПодробнее

Role of PARP Inhibitors in Prostate CancerПодробнее